Effects of budesonide/formoterol on lung volume and serum miR-146 and interleukin-4 levels in patients with bronchiectasis and asthma
10.3760/cma.j.cn341190-20241205-01625
- VernacularTitle:布地奈德福莫特罗对支气管扩张合并哮喘患者肺容积及血清miR-146、IL-4水平的影响
- Author:
Menghui LI
1
;
Xia WANG
;
Baoyue WANG
Author Information
1. 铜川市人民医院药学部，铜川 727000
- Publication Type:Journal Article
- Keywords:
Bronchiectasis;
Asthma;
Respiratory function tests;
Drug-related side effects and adverse reactions;
Ribonucleases;
Interleukin-4;
Interferon-gamma;
Budesoni
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(9):1298-1303
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of budesonide/formoterol versus budesonide on lung volume and serum miR-146 and interleukin-4 levels in patients with bronchiectasis and asthma. Methods:This study adopted a prospective design. A total of 102 patients with bronchiectasis and asthma who received treatment at the People's Hospital of Tongchuan from October 2021 to August 2024 were included. The patients were randomly divided into a conventional group and an observation group using an envelope method ( n = 51 per group). The conventional group received budesonide inhalation treatment, while the observation group was given budesonide/formoterol inhalation powder. All patients were treated for 15 days. The lung function, lung volume, miR-146 mRNA, interleukin-4 (IL-4), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and eosinophil percentage (EOS%) levels of both groups were measured before and after treatment, and the incidence of adverse reactions in the two groups was statistically analyzed. Results:Before treatment, there was no statistically significant difference in lung function and lung volume between the two groups (both P > 0.05). After treatment, the forced vital capacity (FVC), peak expiratory flow (PEF), and forced expiratory volume in the first second (FEV 1) /FVC of both groups were significantly higher than those before treatment ( t = 2.54, 16.22, 9.67, 5.75, 29.25, and 16.91, all P < 0.05). Residual volume (RV) and the ratio of RV to total lung capacity (TLC) were significantly lower in both groups after treatment compared with before treatment ( t = 2.24, -2.98, -3.51, -6.79, all P < 0.05). There was no statistically significant difference in TLC in both groups between before and after treatment ( P > 0.05). The observation group had significantly higher FVC [(2.96 ± 0.65) L], PEF [(75.96 ± 6.54) mL/s], and FEV 1/FVC (85.45 ± 6.03) than the conventional group [(2.57 ± 0.61) L, (67.85 ± 6.06) mL/s, (70.86 ± 5.16), t = -3.12, -6.50, -13.13, all P < 0.05]. After treatment, the RV [(2.81 ± 0.32) L] and RV/TLC [(49.13 ± 3.94)] in the observation group were significantly lower than those in the conventional group [(2.95 ± 0.37) L, (52.03 ± 4.16), t = 2.04, 3.62, both P < 0.05]. The difference in TLC between the two groups was not statistically significant ( P > 0.05). Before treatment, there was also no statistically significant difference in miR-146 mRNA levels between the two groups ( P > 0.05). After treatment, miR-146a and miR-146b mRNA levels in both groups were significantly lower compared to their levels before treatment ( t = -9.21, -4.14, -11.02, -7.58, all P < 0.05). In the observation group, the levels of miR-146a mRNA [(1.41 ± 0.26)] and miR-146b mRNA [(1.15 ± 0.26)] after treatment were significantly lower than those in the conventional group [(1.66 ± 0.34), (1.32 ± 0.34), t = 4.17, 2.84, both P < 0.05]. Before treatment, there were no statistically significant differences in IL-4, IFN-γ, TNF-α, and EOS% between the two groups (all P > 0.05). After treatment, IL-4, IFN-γ, TNF-α, and EOS% levels were significantly lower in both groups compared with before treatment ( t = -6.13, -2.56, -18.57, -23.67, -11.20, -3.83, -20.56, -30.00, all P < 0.05). In the observation group, IL-4 [(234.51 ± 34.03) ng/L], IFN-γ [(214.41 ± 31.54) ng/L], TNF-α [(23.65 ± 10.47) ng/L], and EOS% (2.03 ± 0.33) were significantly lower than those in the conventional group [(265.63 ± 37.51) ng/L], (230.12 ± 36.95) ng/L, (39.69 ± 13.41) ng/L, (2.57 ± 0.51), t = 0.49, 12.39, 6.73, 6.35, all P < 0.05]. There was no significant difference in the incidence of adverse reactions between the observation and conventional groups [13.73% (7/51) vs. 7.84% (4/51), χ2 = 0.92, P > 0.05]. Conclusions:Both budesonide/formoterol and budesonide alone can improve lung function and lung volume in patients with bronchiectasis and asthma while reducing levels of miR-146 and IL-4. However, budesonide/formoterol shows superior efficacy.
